86. Pulmonary arterial hypertension Clinical trials / Disease details


Clinical trials : 1,205 Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2051220042
07/06/202209/06/2022Clinical trial of Nitric Oxide inhalation therapy in patients with severe PHA Single-Center, Randomised, Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide therapy in the patients with severe right heart failure due to pulmonary hypertension Pulmonary arterial hypertension (PAH), and Chronic thromboembolic pulmonary hypertension (CTEPH)
PH, Nitric oxide, PAH, CTEPH, Right heart failure;D006976
Study drug: Nitric Oxide (INOflo for inhalation 800ppm)
Start inhalation at a concentration of 20 ppm, and if the blood methemoglobin concentration is below 2%, increase the dose by 10 ppm every 5 minutes to a maximum concentration of 40 ppm.
On withdrawal from inhalation, if hemodynamics and oxygenation are stable, reduce inhalation dose by half every 5 minutes, gradually decreasing to 5 ppm. And then, If hemodynamics and oxygenation are stable at 1 ppm, attempt inhalation withdrawal every 5 minutes.
Ogo TakeshiNULLPending>= 18age oldNot applicableBoth30Phase 2Japan
2EUCTR2018-001387-39-DE
(EUCTR)
15/03/201930/01/2019The effect of oxygen therapy in patients with pulmonary Hypertension.A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA pulmonary arterial hypertension (PAH) and chronic thromboembolicpulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Oxygen, liquid
INN or Proposed INN: OXYGEN
Other descriptive name: Sauerstoff
Thoraxklinik-Heidelberg gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Germany
3NCT03683082
(ClinicalTrials.gov)
June 5, 201820/9/2018Oxygen Treatment and Pulmonary Arterial HypertensionAcute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension PatientsPulmonary Arterial HypertensionDrug: Oxygen supplementation;Drug: Sham O2 (medical air)George Papanicolaou HospitalNULLUnknown status18 Years80 YearsAll10N/AGreece
4NCT00626028
(ClinicalTrials.gov)
September 200420/2/2008Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator TestingComparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator TestingIdiopathic Pulmonary Arterial Hypertension;CardiomyopathyDrug: Nitric Oxide for inhalation;Drug: Oxygen;Drug: Nitric Oxide plus OxygenMallinckrodtNULLCompletedN/A18 YearsAll136Phase 3United States;France;Netherlands;Spain;United Kingdom
5NCT00317486
(ClinicalTrials.gov)
September 200321/4/2006Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyA Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyDrug: bosentanActelionNULLCompleted12 YearsN/ABoth54Phase 4United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom